Altium Capital Management LP Bio Line Rx Ltd. Transaction History

Altium Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.56 - $0.89 $461,427 - $733,340	-823,978 Reduced 26.55%	2,279,657 $2.03 Million
Q4 2022 Feb 14, 2023	SELL	$0.57 - $0.95 $596,007 - $993,345	-1,045,627 Reduced 25.2%	3,103,635 $1.83 Million
Q3 2022 Nov 14, 2022	BUY	$0.88 - $1.91 $3.65 Million - $7.93 Million	4,149,262 New	4,149,262 $3.84 Million

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.